Understood reports GLP-1 drugs like Ozempic may improve ADHD symptoms by quieting food thoughts, but more research is needed for direct effects.

Closing the gender gap in data science and tech requires tackling barriers at every stage, from early education through career advancement, while actively challenging the unconscious biases that ...

Clinical trials are the cornerstone of drug innovation in modern medicine, providing a systematic, evidence-based framework for determining the efficacy and safety of treatments before they reach ...

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...

CHMP adopts positive opinion on Moderna’s mRNA combination vaccine ‘mCOMBRIAX’ against influenza, Covid-19: Cambridge, Massachusetts Wednesday, March 4, 2026, 16:00 Hrs [IST ...

The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call ...

Compugen Ltd. (NASDAQ:CGEN) Q4 2025 Earnings Call Transcript March 2, 2026 Compugen Ltd. beats earnings expectations. Reported EPS is $0.6, expectations were $0.05. Operator: Ladies and gentlemen, ...

BioLife Solutions has executed a successful turnaround by refocusing on core products and divesting non-core assets. Read ...

York Hospital has reported $40 million in operating losses in recent years, and its future depends on the state approving its merger with MaineHealth.

Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data ...

COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, provides business up ...

Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at ...